In the STEP-1 clinical trial of semaglutide, roughly 45% of total weight lost was lean body mass rather than fat
Additionally, these medications act on central appetite regulation centers in the hypothalamus, contributing to reduced caloric intake
While the results so far appear promising, retatrutide is still in Phase 3 clinical trials, and its full long-term safety profile and FDA approval status are still pending
It's funny how [the medication] can take a holiday and remind you what it's really about."
Pre-portioned meals prevent overeating on days when appetite is unpredictable
Summary: Stacking retatrutide and tesamorelin is not supported by any clinical evidence, carries significant safety risks, and involves two agents that are unlicensed in the UK